MedTrace Logo

Rituxmab Versus IL-6 in Treating ILD

NCT05963048 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2023-11-15

No results posted yet for this study

Summary

All SSc patients should know if they have been diagnosed with interstitial lung disease, or pulmonary hypertension and keep results from his/her last pulmonary function test, chest imaging, echocardiogram and stress test

Conditions

Interventions

DRUG

Rituximab

IV infusion 1000 mg

DRUG

IL6 inhibitor

6 mg/kg I V infusion monthly

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Manal Hassanien, MD · Assiut University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2022-12-30
Completion
2023-06-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05963048 on ClinicalTrials.gov